Bryan C. Dickinson

Bryan C. Dickinson

Auto-generated profile, based on publicly available information

Bryan C. Dickinson

University of Chicago

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JOJerzy Osipiuk
Jerzy Osipiuk
SASaara-Anne Azizi
Saara-Anne Azizi
SDSteve Dvorkin
Steve Dvorkin
MEMichael Endres
Michael Endres
RJRobert Jedrzejczak
Robert Jedrzejczak
AJAndrzej Joachimiak
Andrzej Joachimiak
The pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continues to expand. Papain-like protease (PLpro) is one of two SARS-CoV-2 proteases potentially targetable with antivirals. PLpro is an attractive target because it plays an essential role in cleavage and maturation of viral polyproteins, assembly of the replicase-transcriptase complex, and disruption of host responses. We report a substantive body of structural, biochemical, and virus replication studies that identify several inhibitors of the SARS-CoV-2 enzyme. We determined the high resolution structure of wild-type PLpro, the active site C111S mutant, and their complexes with inhibitors. This collection of structures details inhibitors recognition and interactions providing fundamental molecular and mechanistic insight into PLpro. All compounds inhibit the peptidase activity of PLpro in vitro, some block SARS-CoV-2 replication in cell culture assays. These findings will accelerate structure-based drug design efforts targeting PLpro to identify high-affinity inhibitors of clinical value.

20 July 2021 in Science
Verified
Journal Article
Open access
PDF file
NDNir Drayman
Nir Drayman
JDJennifer K. DeMarco
Jennifer K. DeMarco
KJKrysten A. Jones
Krysten A. Jones
SASaara-Anne Azizi
Saara-Anne Azizi
HFHeather M. Froggatt
Heather M. Froggatt
STSavas Tay
Savas Tay
Targeting the main protease of SARS-CoV-2: Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV

23 September 2019 in Nature Methods
Verified
Journal Article
Closed access
PDF file
HZHuiqing Zhou
Huiqing Zhou
SRSimone Rauch
Simone Rauch
QDQing Dai
Qing Dai
XCXiaolong Cui
Xiaolong Cui
ZZZijie Zhang
Zijie Zhang
BDBryan C. Dickinson
Bryan C. Dickinson

1 June 2019 in Cell
Verified
Journal Article
Closed access
SRSimone Rauch
Simone Rauch
EHEmily He
Emily He
MSMichael Srienc
Michael Srienc
HZHuiqing Zhou
Huiqing Zhou
ZZZijie Zhang
Zijie Zhang
BDBryan C. Dickinson
Bryan C. Dickinson

13 February 2017 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
JPJinyue Pu
Jinyue Pu
JZJulia Zinkus-Boltz
Julia Zinkus-Boltz
BDBryan C Dickinson
Bryan C Dickinson
Design of a proximity-dependent split RNA polymerase system and its optimization by phage-assisted continuous evolution (PACE) enabled the development of a family of activity-dependent split RNA polymerase biosensors regulated by small molecules or light. Biosensors that transduce target chemical and biochemical inputs into genetic outputs are essential for bioengineering and synthetic biology. Current biosensor design strategies are often limited by a low signal-to-noise ratio, the extensive optimization required for each new input, and poor performance in mammalian cells. Here we report the development of a proximity-dependent split RNA polymerase (RNAP) as a general platform for biosensor engineering. After discovering that interactions between fused proteins modulate the assembly of a split T7 RNAP, we optimized the split RNAP components for protein–protein interaction detection by phage-assisted continuous evolution (PACE). We then applied the resulting activity-responsive RNAP (AR) system to create biosensors that can be activated by light and small molecules, demonstrating the 'plug-and-play' nature of the platform. Finally, we validated that ARs can interrogate multidimensional protein–protein interactions and trigger RNA nanostructure production, protein synthesis, and gene knockdown in mammalian systems, illustrating the versatility of ARs in synthetic biology applications.

25 February 2022 in Science Advances
Verified
Journal Article
Open access
LNLong Chi Nguyen
Long Chi Nguyen
DYDongbo Yang
Dongbo Yang
VNVlad Nicolaescu
Vlad Nicolaescu
TBThomas J. Best
Thomas J. Best
HGHaley Gula
Haley Gula
MRMarsha Rosner
Marsha Rosner
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ongoing coronavirus disease 2019 (COVID-19) pandemic underscores the need for new treatments. Here, we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2 replication in lung epithelial cells. CBD acts after viral entry, inhibiting viral gene expression and reversing many effects of SARS-CoV-2 on host gene transcription. CBD inhibits SARS-CoV-2 replication in part by up-regulating the host IRE1α ribonuclease endoplasmic reticulum (ER) stress response and interferon signaling pathways. In matched groups of human patients from the National COVID Cohort Collaborative, CBD (100 mg/ml oral solution per medical records) had a significant negative association with positive SARS-CoV-2 tests. This study highlights CBD as a potential preventative agent for early-stage SARS-CoV-2 infection and merits future clinical trials. We caution against current use of non-medical formulations as a preventative or treatment therapy.